Consequently, compared with those treated with BDL alone, BDL mice treated with GW4869 exhibited a lower degree of skeletal muscle injury and atrophy, as manifested by lower serum levels (AST, CK and LDH) and muscle MuRF1 expression and greater body weight, muscle weight, grip strength, and muscle CSA (Figure 3C–H), suggesting that inhibition of hepatic EV secretion is an effective means to alleviate muscle injury and atrophy in cirrhosis. This evidence concerns the gene TRIM63 and Cirrhosis.